Update of the Phase III trial ‘GRETA’ of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women
| Autor: | Antonio Farris, Giulio Isola, Alfonso Pluchinotta, Imma Capasso, Giorgio Mustacchi, A. Scanni |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal Breast Neoplasms Breast cancer Internal medicine medicine Overall survival Delayed surgery Humans Endocrine system Neoplasm Metastasis Aged Neoplasm Staging Randomized Controlled Trials as Topic Early breast cancer Aged 80 and over business.industry General Medicine medicine.disease Surgery Tamoxifen Treatment Outcome Clinical Trials Phase III as Topic Chemotherapy Adjuvant Female business medicine.drug |
| Zdroj: | Future Oncology. 11:933-941 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon.14.266 |
| Popis: | Background: In the Phase III ‘GRETA’ trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. Patients & methods: Focusing on patients still alive in 2003, outcome end points has been recalculated. Results: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. Conclusion: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5–10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|